"Histocompatibility" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.
| Descriptor ID |
D006648
|
| MeSH Number(s) |
G12.875.519
|
| Concept/Terms |
Histocompatibility- Histocompatibility
- Histocompatibilities
- Immunocompatibility
- Immunocompatibilities
- Tissue Compatibility
- Compatibilities, Tissue
- Compatibility, Tissue
- Tissue Compatibilities
|
Below are MeSH descriptors whose meaning is more general than "Histocompatibility".
Below are MeSH descriptors whose meaning is more specific than "Histocompatibility".
This graph shows the total number of publications written about "Histocompatibility" by people in this website by year, and whether "Histocompatibility" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 3 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 3 | 2 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 3 | 2 | 5 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histocompatibility" by people in Profiles.
-
SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clin Lymphoma Myeloma Leuk. 2024 Dec; 24(12):821-826.
-
SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.
-
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation. Front Immunol. 2020; 11:636.
-
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
-
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective. Biol Blood Marrow Transplant. 2019 05; 25(5):868-882.
-
Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2019 03; 25(3):505-514.
-
Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 03; 25(3):488-495.
-
Non-HLA genetic mismatches and BMT outcome. Blood. 2018 05 31; 131(22):2409-2411.
-
De novo recipient-specific Glutathione S-transferase T1 antibody development after HLA-identical hematopoietic cell transplantation. Transpl Immunol. 2018 02; 46:36-41.
-
The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation. 2017 09; 101(9):2207-2212.